From the somatic mutation and copy number alteration data, we confirmed that glioma-related mutations in TP53, ATRX, EGFR, PDGFRA, and others previously not recognized, including RYR2, IGSF10, BNC2, CADPS2, COL12A1, TRABD2A, and USP34, were significantly enriched in the higher ANXA1 expression group, while the deletion in CDKNA2A/B correlated with higher ANXA1 expression. The gene discussed is ANXA1; the disease is central nervous system cancer.